Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with IgG4-Related Disease (IgG4-RD).

8 Mar 2016

Leukemia researchers uncover protein that allows blood cancers to develop

Walter and Eliza Hall Institute researchers have uncovered a protein that is key to the development of blood cancers caused by a common genetic error.

7 Mar 2016

RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

The U.S. Food and Drug Administration has approved IMBRUVICA (ibrutinib) capsules for treatment-naïve patients with chronic lymphocytic leukemia (CLL).

4 Mar 2016

Rice university researchers uncover elusive lung cancer cells

Researchers at Rice University and the University of Texas MD Anderson Cancer Center have uncovered a trick used by lung cancer cells to hide from the body's immune system.

3 Mar 2016

Researchers find Achilles' heel of acute lymphoblastic leukemia

Researchers at The Ottawa Hospital and the University of Ottawa have found the Achilles' heel of one of the most aggressive forms of leukemia that affects both children and adults. They have also identified a possible new treatment that exploits this fatal weakness.

2 Mar 2016

Potential link between PLCD and ALL could offer new targets for cancer prevention research

A potential correlation between pre-labor cesarean delivery (PLCD) and acute lymphoblastic leukemia (ALL) could offer new targets for cancer prevention research, according to new research from the Masonic Cancer Center, University of Minnesota.

27 Feb 2016

EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

AbbVie, a global biopharmaceutical company, today announced the European Medicines Agency has granted Orphan Drug Designation to venetoclax, an investigational, oral B-cell lymphoma-2 (BCL-2) inhibitor, for the treatment of acute myeloid leukemia (AML).

26 Feb 2016

Protein p62 acts as molecular brake to keep inflammation in check, avoid collateral damage

Inflammation is a Catch-22: the body needs it to eliminate invasive organisms and foreign irritants, but excessive inflammation can harm healthy cells, contributing to aging and sometimes leading to organ failure and death. Researchers at University of California, San Diego School of Medicine have discovered that a protein known as p62 acts as a molecular brake to keep inflammation in check and avoid collateral damage.

26 Feb 2016

IMP's Johannes Zuber receives German Cancer Prize 2016

Johannes Zuber, group leader at the Research Institute of Molecular Pathology (IMP) in Vienna, receives the German Cancer Prize 2016 in the category of experimental cancer research.

24 Feb 2016

Asterias announces successful completion of End-of-Phase 2 meeting with FDA for AML therapy

Asterias Biotherapeutics, Inc. today announced the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for AST-VAC1, its investigational therapy targeting acute myeloid leukemia (AML).

24 Feb 2016

Researchers launch clinical trials to test novel cellular-immunotherapy to treat three types of blood cancer

Cancer immunology is based upon boosting the body's own immune system to vanquish malignancies. It is among the fastest growing areas of oncology research. Researchers at UC San Diego Moores Cancer Center have launched three clinical trials to test the safety and efficacy of a novel cellular-immunotherapy that uses modified T cells - one of the immune system's primary weapons - to treat three different types of blood cancer that often defy existing therapies.

24 Feb 2016

Ohio State researchers working on new way to treat drug-resistant cancer

Researchers at The Ohio State University are working on a new way to treat drug-resistant cancer that the ancient Greeks would approve of--only it's not a Trojan horse, but DNA that hides the invading force.

24 Feb 2016

Researchers Pinpoint Potential Enzyme For T-Cell Leukemia Treatment

For the first time, researchers at Boston University have shown that T-cell leukemia cells use a particular cycle, called the TCA or Kreb cycle, to support their growth and survival.

23 Feb 2016

Researchers analyze how Topo II enzyme may affect stability of genomes

While researchers are now familiar with how cancer begins—cells mutate and then multiply wildly out of control—it is still uncertain exactly how that mutation starts in the molecules of the cells.

22 Feb 2016

Australian researchers reveal how nutlins pave way for improving future of cancer treatment

Australian researchers have resolved a mystery about how a promising new class of anti-cancer drugs, called nutlins, work - paving the way for improving the future of cancer treatment.

22 Feb 2016

Novartis receives FDA Breakthrough Therapy designation for PKC412 (midostaurin)

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy designation to PKC412 (midostaurin). PKC412 (midostaurin) is an investigational treatment for adults with newly-diagnosed AML who are FLT3 mutation-positive, as detected by an FDA-approved test, and who are eligible to receive standard induction and consolidation chemotherapy.

19 Feb 2016

CHLA, Thermo Fisher Scientific agree to develop NGS-based panel for pediatric cancer research

Children's Hospital Los Angeles and Thermo Fisher Scientific have agreed to develop a next-generation sequencing (NGS)-based panel designed specifically for pediatric cancer research. The assay would be CHLA's first NGS panel designed to target biomarkers associated with childhood cancers.

19 Feb 2016

Leukemia News and Research

Further Reading

Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Leukemia researchers uncover protein that allows blood cancers to develop

RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

Rice university researchers uncover elusive lung cancer cells

Researchers find Achilles' heel of acute lymphoblastic leukemia

Potential link between PLCD and ALL could offer new targets for cancer prevention research

EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

Protein p62 acts as molecular brake to keep inflammation in check, avoid collateral damage

IMP's Johannes Zuber receives German Cancer Prize 2016

Asterias announces successful completion of End-of-Phase 2 meeting with FDA for AML therapy

Researchers launch clinical trials to test novel cellular-immunotherapy to treat three types of blood cancer

Ohio State researchers working on new way to treat drug-resistant cancer

Researchers Pinpoint Potential Enzyme For T-Cell Leukemia Treatment

Researchers analyze how Topo II enzyme may affect stability of genomes

Australian researchers reveal how nutlins pave way for improving future of cancer treatment

Novartis receives FDA Breakthrough Therapy designation for PKC412 (midostaurin)

CHLA, Thermo Fisher Scientific agree to develop NGS-based panel for pediatric cancer research

Mtss1 'tumour suppressor' for CML

Asterias Biotherapeutics simplifies capital structure through previously announced Asset Swap with BioTime

CTI BioPharma announces Q4 and FY 2015 earnings

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News